Genetic Attenuation of Plasmodium by B9 Gene Disruption

Disclosed herein are mutant -species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated sporozoites as well as methods of using the same are likewise provided. 116-. (canceled)17PlasmodiumPlasmodiumPlasmodiumPlasmodiumPlasmodiumPlasmodium. A method of generating an immune response to a species parasite of human host range , said method comprising administering to a human subject by a route of administration one or more doses of a vaccine comprising aseptic , purified , live , mutant sporozoite-stage -species parasites genetically engineered to disrupt the functions of a first gene and a second gene , wherein said first gene is a 6-Cys gene selected from the group consisting of b9 and lisp2 , and expression of said second gene is essential for passage through the liver stage of a wild type -species parasites and into the blood stage of the wild type -species parasite development , such that when said mutant sporozoite-stage parasites infect said human subject they invade the hepatocytes of said human subject but developmentally arrest during the liver stage and do not enter the blood stage; and wherein an immune response to said -species , sporozoite-stage parasites of human host range is generated thereby.18. (canceled)19. The method of wherein said first gene is b9.20. (canceled)21. The method of wherein said second gene is slarp.2223-. (canceled)24PlasmodiumP. falciparum.. The method of wherein the species of said parasite is25. The method of wherein the route of administration is selected from the group consisting of subcutaneous claim 17 , intradermal claim 17 , intramuscular and intravenous.26. The method of wherein the route of administration is intravenous.2729-. ...

Genetic Attenuation of Plasmodium by B9 Gene Disruption

Disclosed herein are mutant -species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated sporozoites as well as methods of using the same are likewise provided. 1PlasmodiumPlasmodiumPlasmodiumPlasmodiumPlasmodium. A mutant -species organism genetically engineered to disrupt the functions of a first gene and a second gene , wherein said first gene is a 6-Cys gene , and expression of said second gene is essential for passage of said wild type of said -species organism through the liver stage and into the blood stage of development of said -species organism; wherein said mutant -species organism can infect a host subject and invade host hepatocytes of said subject but said mutant organism developmentally arrests during liver stage and does not enter blood stage.2Plasmodium. The mutant -species organism of wherein said first gene is selected from the group consisting of b9 claim 1 , lisp2 claim 1 , p52 claim 1 , and p36.3Plasmodium. The mutant -species organism of wherein said first gene is b9.43Plasmodium. The mutant -species organism of any one of - wherein said second gene is selected from the group consisting of slarp claims 1 , lisp1 claims 1 , lisp2 claims 1 ,lsa1 claims 1 , and lsa3.5Plasmodium. The mutant -species organism of wherein said second gene is slarp.6Plasmodium. The mutant -species organism of wherein said second gene is slarp.7PlasmodiumP. falciparum, P. vivax, P. ovale, P. malariaeP. knowlesi.. The mutant -species organism of wherein the species is selected from the group consisting of and8PlasmodiumP. falciparum.. The mutant -species organism of wherein the species is9PlasmodiumPlasmodiumPlasmodiumPlasmodiumPlasmodium. A mutant -species organism of human ...

Genetic attenuation of plasmodium by b9 gene disruption

Genetic attenuation of plasmodium by b9 gene disruption

Disclosed herein are mutant Plasmodium -species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.

Genetic attenuation of plasmodium by B9 gene disruption

Disclosed herein are mutant Plasmodium -species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.

Genetic attenuation of Plasmodium by B9 gene disruption

Disclosed herein are mutant Plasmodium -species parasites that are genetically attenuated (GAP). They retain the ability to infect a host and invade host hepatocytes but subsequently their development is completely arrested within the liver stage of Plasmodium development and the parasites do not reach the blood stage of development. Vaccines and pharmaceutical compositions comprising genetically attenuated Plasmodium sporozoites as well as methods of using the same are likewise provided.